6 full analysis of the 2020 health care negotiations

2020 health care negotiations, in the total plate of the health insurance fund is basically unchanged, improve the gold content and accessability of health insurance varieties, encourage innovation, by the multi-party affirmation of one, cage for birds 2020 health insurance negotiations a total of 119 varieties, about 28 billion yuan need for health insurance funds.
At the same time, the transfer of 29 varieties, the catalog of 14 varieties to reduce prices (down 43.46%), and more than 760 varieties of health insurance payment restrictions, probably freeing up the health insurance fund is also more than 28 billion yuan, basically achieved the balance of access, without additional increase in the burden of health insurance funds, through the adjustment of the structure of health insurance varieties, to meet more unsolt clinical needs, the real realization of the cage for birds.
2. Of the 119 varieties transferred to the current negotiations, 40 and 79 were Chinese and Western medicines, accounting for 34% and 66% respectively, and Chinese medicine accounted for a higher proportion than in previous negotiations, reflecting the state's support and encouragement to the Chinese medicine industry, and 18 of the 70 new varieties successful in the 2019 negotiations, Chinese medicine accounted for only 26%.
. Chinese and Western medicines accounted for 84 and 35 of the 119 successfully negotiated varieties, accounting for 71% and 29% respectively, compared with 70 varieties successfully negotiated in 2019 Domestic only 34, only 49%, and then a few negotiations, the proportion of domestic varieties is not high, it can be seen that in recent years, China's pharmaceutical innovation has made significant progress, China is in the golden period of pharmaceutical innovation, with more domestic innovative drugs listed, the future negotiations will have more national brands debut.
. Variety category Of this negotiation, the largest number of cancer drugs included, up to 17, followed by digestion/metabolism 12, immunosuppressants 8 and antiviral drugs 6, which since April 2018 the national anti-cancer drugs from imports, review and approval and clinical use of the series of support is indecisive, the most intense competition in this negotiation is also anti-cancer drugs, such as PD-1.
3, the transfer out of the previous negotiations are mainly incremental, this negotiation is to increase the incremental mainly, is a health care catalog history, not only into the new products, but also the clinical value and cost-effective many varieties transferred out of the catalog, in addition to the transfer of 29 varieties, 14 old varieties in the catalog to reduce prices In addition, the negotiations also on more than 760 varieties of medical insurance payment restrictions, of which, 302 Western medicine adaptive disorders increased restrictions, 210 Chinese medicine can only be used in outpatient and fixed-point medical insurance pharmacies, in particular, 40 Chinese medicine injections are limited to the use of hospitals above the second level, which also saves a certain amount of health insurance funds.
. Has the number of health insurance varieties been sufficient since 2000, China has carried out a number of adjustments to the health insurance catalogue, and the number of varieties included in health insurance has increased from 1,535 in 2000 to 2,800 today, an increase of 82%, of which The number of Chinese medicines has also increased from 622 in 2000 to 1,374 today, an increase of 1.2 times, and the proportion of Chinese medicines in the total number of varieties in the health insurance catalogue has increased from 41% in 2000 to 49% today.
The current health insurance directory is only 91 net increase than in 2019, an increase of less than 4%, far less than the previous health insurance catalog adjustment when the increase, one indicates that China's health insurance catalog adjustment has been changed from the original increment-based to quality-based, but also related to clinical actual needs.
According to the Statistics of the Chinese Pharmaceutical Society, in 2019, the number of medical insurance varieties in use in china's second- and lower-level hospitals was 1227 and 1265 in the third-tier hospitals. 74 species, simply compared by quantity, account for less than half (45.5%) of the 2,800 varieties in the current health insurance catalogue, so it is expected that the future adjustment of the health insurance directory will continue to adhere to the principle of quality-based, incremental supplement.
the 2020 health care negotiations have become a thing of the past, but it will have a profound impact on the industry and society as a whole, people's confidence in China's drug access is multiplied, pharmaceutical companies research and development strategy should also refer to the direction of health insurance.
。